pentoxifylline has been researched along with Disease Exacerbation in 52 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, -23." | 9.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an inhibitor of tumor necrosis factor (TNF), in severe acute alcoholic hepatitis." | 9.09 | Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. ( Akriviadis, E; Botla, R; Briggs, W; Han, S; Reynolds, T; Shakil, O, 2000) |
| " Since Pentoxifylline, a methyl-xanthine derivative known for enhancement of vascular endothelial function, down-regulation of many inflammatory cytokines increased during preeclampsia, improvement of placental circulation, reduction of ischemia-reperfusion injury, enhancement of vasodilatation and endothelial function, ameliorating proteinuria, inhibition of platelet aggregation and decreasing risk of preterm labor, which are all amongst morbidities of preeclampsia, here it is hypothesized that Pentoxifylline prevents development of preeclampsia and/or decelerate progression of the disease." | 7.81 | Hypothesis: Pentoxifylline explores new horizons in treatment of preeclampsia. ( Azimi, A; Farhadi, P; Sagheb, MM; Ziaee, SM, 2015) |
| "Feeding mice a methionine choline deficient (MCD) diet serves as a nutritional model of non-alcoholic steatohepatitis (NASH)." | 7.72 | Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. ( Green, RM; Koppe, SW; Malladi, P; Sahai, A; Whitington, PF, 2004) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 6.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-κB-p65/p38-MAPK signaling pathways." | 5.48 | Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. ( Abo-Youssef, AM; Ali, FEM; Azouz, AA; Bakr, AG; Hemeida, RAM, 2018) |
| " In the first stage, pentoxifylline decreased median proteinuria from 1,140 to 800 mg/g (median change, -23." | 5.13 | Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. ( Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ; Wu, KD, 2008) |
| "An earlier pilot study from our liver unit suggested benefit from treatment with pentoxifylline (PTX), an inhibitor of tumor necrosis factor (TNF), in severe acute alcoholic hepatitis." | 5.09 | Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. ( Akriviadis, E; Botla, R; Briggs, W; Han, S; Reynolds, T; Shakil, O, 2000) |
| " Since Pentoxifylline, a methyl-xanthine derivative known for enhancement of vascular endothelial function, down-regulation of many inflammatory cytokines increased during preeclampsia, improvement of placental circulation, reduction of ischemia-reperfusion injury, enhancement of vasodilatation and endothelial function, ameliorating proteinuria, inhibition of platelet aggregation and decreasing risk of preterm labor, which are all amongst morbidities of preeclampsia, here it is hypothesized that Pentoxifylline prevents development of preeclampsia and/or decelerate progression of the disease." | 3.81 | Hypothesis: Pentoxifylline explores new horizons in treatment of preeclampsia. ( Azimi, A; Farhadi, P; Sagheb, MM; Ziaee, SM, 2015) |
| "This study is a retrospective review of treatment outcomes of osteoradionecrosis (ORN) of the mandible with specific reference to the evolving role of medical management with pentoxifylline, tocopherol, and doxycycline." | 3.80 | Changing trends and the role of medical management on the outcome of patients treated for osteoradionecrosis of the mandible: experience from a regional head and neck unit. ( D'Souza, J; Lowe, D; Rogers, SN, 2014) |
| " In the present study, enhancement in the antimetastatic activity of etoposide (ETP) by encapsulation in sterically stabilized liposomes was evaluated in the murine experimental B16F10 melanoma model." | 3.72 | Sterically stabilized etoposide liposomes: evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice. ( Gude, RP; Nagarsenker, MS; Rao, SG; Sant, VP, 2003) |
| "Feeding mice a methionine choline deficient (MCD) diet serves as a nutritional model of non-alcoholic steatohepatitis (NASH)." | 3.72 | Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. ( Green, RM; Koppe, SW; Malladi, P; Sahai, A; Whitington, PF, 2004) |
| "Previous studies have reported that pentoxifylline, a phosphodiesterase inhibitor, attenuates experimental mesangial proliferative glomerulonephritis." | 3.71 | Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. ( Chen, YM; Chiang, WC; Chien, CT; Lin, SL; Tsai, CC; Tsai, TJ, 2002) |
| "PTX treatment of colon cancer patients, in addition to chemotherapy, significantly improved survival rates, induced weight gain and reduced stomatitis occurrence -all important parameters of cachexia." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "Pentoxifylline treatment (400 mg/twice a day) or standard treatment." | 2.90 | Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial. ( Barbieri, D; Carbayo, J; de Jose, AP; de Morales, AM; Delgado, A; Goicoechea, M; Luño, J; Verdalles, U; Verde, E, 2019) |
| "Proteinuria was not different between the pentoxifylline and placebo groups at baseline, 6 months, or 1 year." | 2.74 | Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. ( Aboudara, MC; Cushner, HM; Olson, SW; Perkins, RM; Uy, AL; Yuan, CM, 2009) |
| "However, most patients with NAFLD/NASH will die from a vascular cause." | 2.72 | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. ( Atkin, SL; De Vincentis, A; Jamialahmadi, T; Mahjoubin-Tehran, M; Mantzoros, CS; Mikhailidis, DP; Sahebkar, A, 2021) |
| "The causes of pruritus are numerous including xerosis, drug and photoeruptions, follicular and papular eruptions as well as infestations and infections by a wide range of organisms." | 2.68 | Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. ( Lee, RB; Skelton, HG; Smith, KJ; Wagner, KF; Yeager, J, 1997) |
| "Diabetic nephropathy, or diabetic kidney disease (DKD), is the most serious complication of diabetes mellitus (DM)." | 2.53 | Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug? ( Bhanot, S; Leehey, DJ, 2016) |
| "Severe alcoholic hepatitis (AH) has high mortality." | 2.52 | Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis. ( Atkinson, SR; Bongiorno, CM; Chandar, AK; Loomba, R; Murad, MH; Shah, VH; Singal, AK; Singh, S; Thursz, MR, 2015) |
| "Pentoxifylline is an alternative therapy." | 2.50 | Therapy for alcoholic liver disease. ( Cappell, MS; Jaurigue, MM, 2014) |
| " Conclusion of this review is that short-term use of PTF may produce a significant reduction of proteinuria in subjects with diabetic and also non-diabetic kidney diseases but the reports of long-term use of PTF also show that urinary protein excretion exhibits a progressive and sustained reduction in patients treated with PTF." | 2.47 | A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria. ( Abdollahi, M; Badri, S; Dashti-Khavidaki, S; Lessan-Pezeshki, M, 2011) |
| "Diabetic nephropathy is the leading cause of end-stage renal disease, and both the incidence and prevalence of diabetic nephropathy continue to increase." | 2.46 | Potential new therapeutic agents for diabetic kidney disease. ( Bolton, WK; Turgut, F, 2010) |
| "However, the ultimate solution to halt disease progression in the long term is still pending." | 2.42 | Pentoxifylline: a potential therapy for chronic kidney disease. ( Chen, WY; Chen, YM; Chiang, WC; Lin, SL; Tsai, TJ, 2004) |
| "DS and PTX could mitigate liver cirrhosis through modulation of Keap-1/Nrf-2/GSH and NF-κB-p65/p38-MAPK signaling pathways." | 1.48 | Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis. ( Abo-Youssef, AM; Ali, FEM; Azouz, AA; Bakr, AG; Hemeida, RAM, 2018) |
| "At present there is no therapy for Alzheimer's Disease which completely stops the progressive dementia effecting late onset Alzheimer's Disease (AD) patients." | 1.46 | A unique and promising combination of medications for the treatment of Alzheimer's disease. ( Weinstein, JD, 2017) |
| "In terms of the risks of developing ESRD, pentoxifylline alone exerted a comparable beneficial effect to combined therapy with an RAAS inhibitor and greater renoprotection than RAAS inhibitor monotherapy." | 1.42 | Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease. ( Chen, CY; Chen, L; Chen, YM; Huang, TM; Lin, CJ; Lin, SL; Pan, CF; Wu, CH; Wu, CJ; Wu, PC; Wu, VC, 2015) |
| "Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease." | 1.38 | Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. ( Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I, 2012) |
| "Pentoxifylline (POF) is a new candidate for the treatment of nonalcoholic steatohepatitis (NASH)." | 1.34 | Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. ( Birben, E; Celikel, C; Duman, DG; Ekşioğlu-Demiralp, E; Kalayci, C; Kalayci, O; Keskin, O; Ozdemir, F, 2007) |
| "The question whether progressive sensorineural hearing loss during childhood is the fateful course of a main illness has been discussed controversially over 60 years." | 1.31 | Progressive hearing loss in hearing impaired children: immediate results of antiphlogistic--rheologic infusion therapy. ( Michel, O; Schöndorf, HJ; Stennert, E; Streppel, M; von Wedel, H; Walger, M; Wittekindt, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (7.69) | 18.2507 |
| 2000's | 19 (36.54) | 29.6817 |
| 2010's | 26 (50.00) | 24.3611 |
| 2020's | 3 (5.77) | 2.80 |
| Authors | Studies |
|---|---|
| Fouda, A | 1 |
| Abdelaziz, AE | 1 |
| Hussien, M | 1 |
| Ali, AA | 1 |
| Abdelkawy, KS | 1 |
| Elbarbry, F | 1 |
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| Yang, H | 1 |
| Juang, SY | 1 |
| Liao, KF | 1 |
| Chen, YH | 1 |
| Mahjoubin-Tehran, M | 1 |
| De Vincentis, A | 1 |
| Mikhailidis, DP | 1 |
| Atkin, SL | 1 |
| Mantzoros, CS | 1 |
| Jamialahmadi, T | 1 |
| Sahebkar, A | 1 |
| Chen, YM | 5 |
| Chiang, WC | 4 |
| Lin, SL | 5 |
| Tsai, TJ | 4 |
| Weinstein, JD | 1 |
| Lin, YC | 1 |
| Chang, YH | 1 |
| Yang, SY | 1 |
| Wu, KD | 2 |
| Chu, TS | 1 |
| Ali, FEM | 1 |
| Bakr, AG | 1 |
| Abo-Youssef, AM | 1 |
| Azouz, AA | 1 |
| Hemeida, RAM | 1 |
| de Morales, AM | 1 |
| Goicoechea, M | 1 |
| Verde, E | 1 |
| Carbayo, J | 1 |
| Barbieri, D | 1 |
| Delgado, A | 1 |
| Verdalles, U | 1 |
| de Jose, AP | 1 |
| Luño, J | 1 |
| Murkamilov, IT | 1 |
| Aitbaev, KA | 1 |
| Fomin, VV | 1 |
| Murkamilova, ZA | 1 |
| Bayzhigitova, AA | 1 |
| D'Souza, J | 1 |
| Lowe, D | 1 |
| Rogers, SN | 1 |
| Jaurigue, MM | 1 |
| Cappell, MS | 1 |
| Navarro-González, JF | 1 |
| Mora-Fernández, C | 1 |
| Muros de Fuentes, M | 1 |
| Chahin, J | 1 |
| Méndez, ML | 1 |
| Gallego, E | 1 |
| Macía, M | 1 |
| del Castillo, N | 1 |
| Rivero, A | 1 |
| Getino, MA | 1 |
| García, P | 1 |
| Jarque, A | 1 |
| García, J | 1 |
| He, T | 1 |
| Cooper, ME | 1 |
| Wu, PC | 1 |
| Wu, CJ | 1 |
| Lin, CJ | 1 |
| Pan, CF | 1 |
| Chen, CY | 1 |
| Huang, TM | 1 |
| Wu, CH | 1 |
| Chen, L | 1 |
| Wu, VC | 1 |
| Singh, S | 1 |
| Murad, MH | 1 |
| Chandar, AK | 1 |
| Bongiorno, CM | 1 |
| Singal, AK | 1 |
| Atkinson, SR | 1 |
| Thursz, MR | 1 |
| Loomba, R | 1 |
| Shah, VH | 1 |
| Azimi, A | 1 |
| Ziaee, SM | 1 |
| Farhadi, P | 1 |
| Sagheb, MM | 1 |
| Kuo, KL | 1 |
| Hung, SC | 1 |
| Liu, JS | 1 |
| Chang, YK | 1 |
| Hsu, CC | 1 |
| Tarng, DC | 1 |
| Bhanot, S | 1 |
| Leehey, DJ | 1 |
| Pena-Polanco, JE | 1 |
| Fried, LF | 1 |
| Perkins, RM | 1 |
| Aboudara, MC | 1 |
| Uy, AL | 1 |
| Olson, SW | 1 |
| Cushner, HM | 1 |
| Yuan, CM | 1 |
| Turgut, F | 1 |
| Bolton, WK | 1 |
| Olin, JW | 1 |
| Sealove, BA | 1 |
| Bisaga, GN | 1 |
| Odinak, MM | 1 |
| Boĭko, AN | 1 |
| Mel'nik, IuB | 1 |
| Popova, NF | 1 |
| Badri, S | 1 |
| Dashti-Khavidaki, S | 1 |
| Lessan-Pezeshki, M | 1 |
| Abdollahi, M | 1 |
| Marcocci, C | 1 |
| Kahaly, GJ | 1 |
| Krassas, GE | 1 |
| Bartalena, L | 1 |
| Prummel, M | 1 |
| Stahl, M | 1 |
| Altea, MA | 1 |
| Nardi, M | 1 |
| Pitz, S | 1 |
| Boboridis, K | 1 |
| Sivelli, P | 1 |
| von Arx, G | 1 |
| Mourits, MP | 1 |
| Baldeschi, L | 1 |
| Bencivelli, W | 1 |
| Wiersinga, W | 1 |
| Levine, LA | 1 |
| Tahir, F | 1 |
| Riaz, H | 1 |
| Rehman, A | 1 |
| Munir, MB | 1 |
| Keravis, T | 1 |
| Monneaux, F | 1 |
| Yougbaré, I | 1 |
| Gazi, L | 1 |
| Bourguignon, JJ | 1 |
| Muller, S | 1 |
| Lugnier, C | 1 |
| Escolar, DM | 1 |
| Zimmerman, A | 1 |
| Bertorini, T | 1 |
| Clemens, PR | 1 |
| Connolly, AM | 1 |
| Mesa, L | 1 |
| Gorni, K | 1 |
| Kornberg, A | 1 |
| Kolski, H | 1 |
| Kuntz, N | 1 |
| Nevo, Y | 1 |
| Tesi-Rocha, C | 1 |
| Nagaraju, K | 1 |
| Rayavarapu, S | 1 |
| Hache, LP | 1 |
| Mayhew, JE | 1 |
| Florence, J | 1 |
| Hu, F | 1 |
| Arrieta, A | 1 |
| Henricson, E | 1 |
| Leshner, RT | 1 |
| Mah, JK | 1 |
| Melnik, B | 1 |
| Hariry, H | 1 |
| Vakilzadeh, F | 1 |
| Gropp, C | 1 |
| Sitzer, G | 1 |
| Chien, CT | 1 |
| Tsai, CC | 1 |
| Mann, DL | 1 |
| Andela, VB | 1 |
| Gingold, BI | 1 |
| Souza, MD | 1 |
| O'Keefe, RJ | 1 |
| Puzas, EJ | 1 |
| Schwarz, EM | 1 |
| Rosier, RN | 1 |
| Sant, VP | 1 |
| Nagarsenker, MS | 1 |
| Rao, SG | 1 |
| Gude, RP | 1 |
| Chen, WY | 1 |
| Koppe, SW | 1 |
| Sahai, A | 1 |
| Malladi, P | 1 |
| Whitington, PF | 1 |
| Green, RM | 1 |
| Yalniz, M | 1 |
| Bahçecioğlu, IH | 1 |
| Kuzu, N | 1 |
| Celebi, S | 1 |
| Ataseven, H | 1 |
| Ustündağ, B | 1 |
| Ozercan, IH | 1 |
| Sahin, K | 1 |
| Duman, DG | 1 |
| Ozdemir, F | 1 |
| Birben, E | 1 |
| Keskin, O | 1 |
| Ekşioğlu-Demiralp, E | 1 |
| Celikel, C | 1 |
| Kalayci, O | 1 |
| Kalayci, C | 1 |
| Kibrik, BS | 1 |
| Chelnokova, OG | 1 |
| Konstan, MW | 1 |
| McDaniel, MD | 1 |
| Smith, KJ | 1 |
| Skelton, HG | 1 |
| Yeager, J | 1 |
| Lee, RB | 1 |
| Wagner, KF | 1 |
| Myers, LW | 1 |
| Ellison, GW | 1 |
| Merrill, JE | 1 |
| El Hajjar, A | 1 |
| St Pierre, B | 1 |
| Hijazin, M | 1 |
| Leake, BD | 1 |
| Bentson, JR | 1 |
| Nuwer, MR | 1 |
| Tourtellotte, WW | 1 |
| Davis, P | 1 |
| Granger, D | 1 |
| Fahey, JL | 1 |
| Akriviadis, E | 1 |
| Botla, R | 1 |
| Briggs, W | 1 |
| Han, S | 1 |
| Reynolds, T | 1 |
| Shakil, O | 1 |
| Streppel, M | 1 |
| Wittekindt, C | 1 |
| von Wedel, H | 1 |
| Walger, M | 1 |
| Schöndorf, HJ | 1 |
| Michel, O | 1 |
| Stennert, E | 1 |
| Basak, PY | 1 |
| Ergin, S | 1 |
| Turner, J | 1 |
| Frank, AA | 1 |
| Brooks, JV | 1 |
| Marietta, PM | 1 |
| Orme, IM | 1 |
| Souza, CS | 1 |
| Roselino, AM | 1 |
| Figueiredo, F | 1 |
| Foss, NT | 1 |
| Laurat, E | 1 |
| Poirier, B | 1 |
| Tupin, E | 1 |
| Caligiuri, G | 1 |
| Hansson, GK | 1 |
| Bariéty, J | 1 |
| Nicoletti, A | 1 |
| Fernandez, BB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria[NCT05298163] | 120 participants (Anticipated) | Interventional | 2022-04-30 | Not yet recruiting | |||
| Pentoxifylline and Progression of Chronic Kidney Disease in Moderate-to-high Risk Patients: a Pilot Randomized, Placebo-controlled, Double-blind Trial.[NCT00285298] | Phase 3 | 39 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Selenium - ITEDS: A North American Study[NCT02112643] | Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to Lack of funding) | ||
| Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial[NCT02473341] | Phase 3 | 174 participants (Actual) | Interventional | 2017-11-14 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
13 reviews available for pentoxifylline and Disease Exacerbation
| Article | Year |
|---|---|
Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Topics: Biopsy; Disease Progression; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Di | 2021 |
Therapeutic efficacy of pentoxifylline on proteinuria and renal progression: an update.
Topics: Disease Progression; Kidney Failure, Chronic; Pentoxifylline; Phosphodiesterase Inhibitors; Proteinu | 2017 |
Update of pathophysiology and management of diabetic kidney disease.
Topics: Albuminuria; Biomarkers; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failure, Chroni | 2018 |
Pentoxifylline and nephroprotection: effects on renal dysfunction and cardiovascular risks.
Topics: Cardiovascular Diseases; Disease Progression; Humans; Kidney; Pentoxifylline; Renal Insufficiency, C | 2019 |
Therapy for alcoholic liver disease.
Topics: Adrenal Cortex Hormones; Alcohol Abstinence; Alcohol Deterrents; Animals; Disease Progression; Human | 2014 |
Comparative Effectiveness of Pharmacological Interventions for Severe Alcoholic Hepatitis: A Systematic Review and Network Meta-analysis.
Topics: Acetylcysteine; Adrenal Cortex Hormones; Comparative Effectiveness Research; Disease Progression; Dr | 2015 |
Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Topics: Animals; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Humans; Kidney Failu | 2016 |
Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.
Topics: Allopurinol; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bicarbonate | 2016 |
Potential new therapeutic agents for diabetic kidney disease.
Topics: Amides; Animals; Clinical Trials as Topic; Connective Tissue Growth Factor; Diabetic Nephropathies; | 2010 |
A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria.
Topics: Animals; Chronic Disease; Diabetic Nephropathies; Disease Progression; Humans; Kidney Diseases; Kidn | 2011 |
Inflammatory mediators and the failing heart: past, present, and the foreseeable future.
Topics: Animals; Antibodies, Monoclonal; Antirheumatic Agents; Clinical Trials as Topic; Cytokines; Disease | 2002 |
Pentoxifylline: a potential therapy for chronic kidney disease.
Topics: Animals; Anti-Inflammatory Agents; Cell Division; Disease Progression; Extracellular Matrix; Glomeru | 2004 |
Treatment of airway inflammation in cystic fibrosis.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Anti-Inflammatory Agents; Anti-Inf | 1996 |
12 trials available for pentoxifylline and Disease Exacerbation
| Article | Year |
|---|---|
A randomized controlled trial comparing the effects of Vitamin E, Ursodeoxycholic acid and Pentoxifylline on Egyptian non-alcoholic steatohepatitis patients.
Topics: Adult; Antioxidants; Cholagogues and Choleretics; Disease Progression; Egypt; Female; Humans; Male; | 2021 |
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Pentoxifylline, progression of chronic kidney disease (CKD) and cardiovascular mortality: long-term follow-up of a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Albuminuria; Cardiovascular Diseases; Creatinine; Disease Progression; Foll | 2019 |
Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.
Topics: Aged; Albumins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Glom | 2015 |
Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Chemokine CCL2; | 2008 |
Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Dis | 2009 |
[Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antioxidants; Autoantibodies; Cognition; Disease Progres | 2011 |
Selenium and the course of mild Graves' orbitopathy.
Topics: Adult; Anti-Inflammatory Agents; Antioxidants; Disease Progression; Double-Blind Method; Female; Gra | 2011 |
Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial.
Topics: Adrenal Cortex Hormones; Child; Delayed-Action Preparations; Disease Progression; Double-Blind Metho | 2012 |
Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation.
Topics: Administration, Cutaneous; Administration, Topical; Anti-Inflammatory Agents; Antipruritics; Cycloox | 1997 |
Pentoxifylline is not a promising treatment for multiple sclerosis in progression phase.
Topics: Adult; Brain; Disease Progression; Dose-Response Relationship, Drug; Evoked Potentials, Visual; Huma | 1998 |
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial.
Topics: Acute Disease; Adult; Cohort Studies; Disease Progression; Double-Blind Method; Female; Hepatitis, A | 2000 |
27 other studies available for pentoxifylline and Disease Exacerbation
| Article | Year |
|---|---|
Comparing the Effect of Folic Acid and Pentoxifylline on Delaying Dialysis Initiation in Patients with Advanced Chronic Kidney Disease.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease Progression; Female; Folic Acid; | 2019 |
A unique and promising combination of medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Dementia; Disease Progression; Drug Design; Drug Therapy, Combination; Hum | 2017 |
Targeting Keap-1/Nrf-2 pathway and cytoglobin as a potential protective mechanism of diosmin and pentoxifylline against cholestatic liver cirrhosis.
Topics: Animals; Cytoglobin; Diosmin; Disease Progression; Free Radicals; Gene Expression Profiling; Globins | 2018 |
Changing trends and the role of medical management on the outcome of patients treated for osteoradionecrosis of the mandible: experience from a regional head and neck unit.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antioxidants; Carcinoma, Squamous Cell; Debridement; | 2014 |
Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial.
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Free Radi | 2014 |
Pentoxifylline Decreases Dialysis Risk in Patients With Advanced Chronic Kidney Disease.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2015 |
Hypothesis: Pentoxifylline explores new horizons in treatment of preeclampsia.
Topics: Angiogenesis Inhibitors; Animals; Blood Coagulation; Cytokines; Disease Progression; Endothelium, Va | 2015 |
Add-on Protective Effect of Pentoxifylline in Advanced Chronic Kidney Disease Treated with Renin-Angiotensin-Aldosterone System Blockade - A Nationwide Database Analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Creatinine; Databases, Fac | 2015 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progress | 2010 |
Current approach to the man with acute phase Peyronie's disease--case presentation and discussion.
Topics: Adult; Arginine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; H | 2011 |
Potential role of TNF alpha blockers in delaying the progression of hepato-renal syndrome.
Topics: Disease Progression; Double-Blind Method; Hepatorenal Syndrome; Humans; Liver Failure; Pentoxifyllin | 2012 |
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Fem | 2012 |
[Malignant atrophic papulosis (Köhlmeier-Degos disease). Failure to respond to interferon alpha-2a, pentoxifylline and aspirin].
Topics: Aspirin; Atrophy; Connective Tissue; Diagnosis, Differential; Disease Progression; Drug Therapy, Com | 2002 |
Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cell Division; Cells, Cultured; C | 2002 |
Clinical relevance of increased retinoid and cAMP transcriptional programs in tumor cells rendered non-malignant by dominant negative inhibition of NFkappaB.
Topics: Animals; Antineoplastic Agents; Collagen; Cyclic AMP; Disease Progression; Drug Combinations; Female | 2003 |
Sterically stabilized etoposide liposomes: evaluation of antimetastatic activity and its potentiation by combination with sterically stabilized pentoxifylline liposomes in mice.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; E | 2003 |
Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
Topics: Alanine Transaminase; Animals; Choline Deficiency; Deficiency Diseases; Diet; Disease Progression; F | 2004 |
Amelioration of steatohepatitis with pentoxifylline in a novel nonalcoholic steatohepatitis model induced by high-fat diet.
Topics: Animals; Dietary Fats; Disease Models, Animal; Disease Progression; Fatty Liver; Follow-Up Studies; | 2007 |
Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis.
Topics: Adult; Biomarkers; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Fatty Li | 2007 |
[Extracorporeal antiaggregant pharmacotherapy in the treatment of acutely progressive forms of tuberculosis].
Topics: Antitubercular Agents; Blood Chemical Analysis; Disease Progression; Drug Therapy, Combination; Huma | 2007 |
A 52-year-old woman with diabetes and claudication.
Topics: Coronary Disease; Decision Making; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Diabetic Nephro | 1998 |
Progressive hearing loss in hearing impaired children: immediate results of antiphlogistic--rheologic infusion therapy.
Topics: Case-Control Studies; Child; Child, Preschool; Disease Progression; Drug Therapy, Combination; Follo | 2001 |
Should pentoxifylline be regarded as an effective treatment for Schamberg's disease?
Topics: Adolescent; Disease Progression; Hematologic Agents; Humans; Male; Pentoxifylline; Pigmentation Diso | 2001 |
Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology.
Topics: Animals; Chemokine CCL2; Chronic Disease; Disease Progression; Female; Interferon-gamma; Lung; Mice; | 2001 |
Lucio's phenomenon: clinical and therapeutic aspects.
Topics: Aged; Anti-Inflammatory Agents; Brazil; Disease Progression; Endothelium, Vascular; Fatal Outcome; F | 2000 |
In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cell Count; Cell Differentiation; Cells, | 2001 |
A rational approach to diagnosis and treatment of intermittent claudication.
Topics: Algorithms; Blood Pressure Determination; Cilostazol; Disease Progression; Exercise Test; Hematologi | 2002 |